C3 Glomerulonephritis — Clinical Trials

MONDO:00138923 active·1 recruitingLast updated: Mar 16, 2026, 4:22 AM

Trial Landscape

C3 Glomerulonephritis has an emerging clinical trial program, driven by drug treatment.

Recruiting

Active Trials

By Approach

Drug Treatment3

By Phase

Phase 2

Phase 3

Sponsor Types

Industry2Academic/Other1

Top Sponsors

Apellis Pharmaceuticals, Inc.

Trial Locations

United States2 trials

Argentina2 trials

Australia2 trials

Brazil2 trials

France2 trials

Italy2 trials

Netherlands2 trials

Spain2 trials

Switzerland2 trials

United Kingdom2 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 2Recruiting

NCT04183101

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Sponsor:Region Skane

SwedenStarted: Oct 2020Est. completion: Dec 2029Updated: Jun 2025

Phase 3Active, Not Recruiting

NCT05809531

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Sponsor:Apellis Pharmaceuticals, Inc.

United StatesStarted: May 2023Est. completion: Jul 2027Updated: Mar 2025

Phase 2Active, Not Recruiting

NCT04572854

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Sponsor:Apellis Pharmaceuticals, Inc.

United StatesStarted: Sep 2021Est. completion: Jan 2026Updated: Mar 2025

Stay informed about clinical trials for C3 Glomerulonephritis.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 4:22 AM